Above all, we make a difference.
Home > Breast Cancer Information > Survivorship Topics > Survivorship References

Survivorship Topics References

  

  1. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 34(6):611-35, 2016.
  2. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer. V.2.2026. http://www.nccn.org, 2026.
  3. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Survivorship. V.1.2026. http://www.nccn.org, 2026.
  4. American Cancer Society. Vaccinations and flu shots for people with cancer. https://www.cancer.org/cancer/managing-cancer/side-effects/infections/vaccination-during-cancer-treatment.html, 2025.
  5. Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ. Quality of life in long-term breast cancer survivors. J Clin Oncol. 31(28):3540-8, 2013.
  6. Park J, Rodriguez JL, O’Brien KM, et al. Health-related quality of life outcomes among breast cancer survivors. Cancer. 127(7):1114-1125, 2021.
  7. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 1(1):CD010802, 2017.
  8. Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 1(1):CD011292, 2018.
  9. Sheppard VB, Dash C, Nomura S, et al. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer. Cancer. 126(17):4059-4066, 2020.
  10. Rock CL, Thomson CA, Sullivan KR, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 72(3):230-262, 2022.
  11. Johansen SH, Reinertsen KV, Wisløff T, et al. Effects of aerobic exercise on late effects and quality of life in long-term breast cancer survivors: a randomized controlled trial. JNCI Cancer Spectr. 9(6):pkaf102, 2025.
  12. Leung J, Smith MD, McLaughlin D. Inequalities in long term health-related quality of life between partnered and not partnered breast cancer survivors through the mediation effect of social support. Psychooncology. 25(10):1222-1228, 2016.
  13. Syrowatka A, Motulsky A, Kurteva S, et al. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat. 165(2):229-245, 2017.
  14. Hurtado-de-Mendoza A, Gonzales F, Song M, et al. Association between aspects of social support and health-related quality of life domains among African American and White breast cancer survivors. J Cancer Surviv. 16(6):1379-1389, 2022.
  15. Shapiro SL, Lopez AM, Schwartz GE, et al. Quality of life and breast cancer: relationship to psychosocial variables. J Clin Psychol. 57(4):501-19, 2001.
  16. Horgan O, Holcombe C, Salmon P. Experiencing positive change after a diagnosis of breast cancer: a grounded theory analysis. Psychooncology. 20(10):1116-25, 2011.
  17. Groarke A, Curtis R, Groarke JM, Hogan MJ, Gibbons A, Kerin M. Post-traumatic growth in breast cancer: how and when do distress and stress contribute? Psychooncology. 26(7):967-974, 2017.
  18. Perkins EA, Small BJ, Balducci L, Extermann M, Robb C, Haley WE. Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol Hematol. 62(1):74-83, 2007.
  19. Asdourian MS, Swaroop MN, Sayegh HE, et al. Association between precautionary behaviors and breast cancer-related lymphedema in patients undergoing bilateral surgery. J Clin Oncol. 35(35):3934-3941, 2017.
  20. Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol. 24(10):2972-2980, 2017.
  21. Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 379(20):1937-1944, 2018.
  22. Naoum GE, Roberts S, Brunelle CL, et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial. J Clin Oncol. 38(29):3430-3438, 2020.
  23. Koelmeyer LA, Gaitatzis K, Dietrich MS, et al. Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. Cancer. 128(18):3408-3415, 2022.
  24. Ren Y, Kebede MA, Ogunleye AA, et al. Burden of lymphedema in long-term breast cancer survivors by race and age. Cancer. 128(23):4119-4128, 2022.
  25. Boyages J, Vicini FA, Manavi BA, et al. Axillary treatment and chronic breast cancer-related lymphedema: implications for prospective surveillance and intervention from a randomized controlled trial. JCO Oncol Pract. 19(12):1116-1124, 2023.
  26. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Survivorship. V.1.2026. http://www.nccn.org, 2026.
  27. Brunelle CL, Mehrara B, Taghian A. Screening for and prevention of breast cancer-related lymphedema. In: UpToDate (Hayes DF, Nekhlyudov L, Bruera E, Ganz PA, Collins KA and Vora SR, eds.). Waltham, MA: UpToDate, 2025.
  28. Miller CL, Colwell AS, Horick N, et al. Immediate implant reconstruction is associated with a reduced risk of lymphedema compared to mastectomy alone: a prospective cohort study. Ann Surg. 263(2):399-405, 2016.
  29. Menezes MM, Bello MA, Millen E, et al. Breast reconstruction and risk of lymphedema after mastectomy: A prospective cohort study with 10 years of follow-up. J Plast Reconstr Aesthet Surg. 69(9):1218-26, 2016.
  30. Siotos C, Sebai ME, Wan EL, et al. Breast reconstruction and risk of arm lymphedema development: A meta-analysis. J Plast Reconstr Aesthet Surg. 71(6):807-818, 2018.
  31. Jeon HB, Jung JH, Im SH, et al. Association between immediate breast reconstruction and the development of breast cancer-Related Lymphedema. Plast Reconstr Surg. 151(2):214e-222e, 2023.
  32. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 14(6):500-15, 2013.
  33. De Gournay E, Guyomard A, Coutant C, et al. Impact of sentinel node biopsy on long-term quality of life in breast cancer patients. Br J Cancer. 109(11):2783-91, 2013.
  34. McLaughlin SA, Bagaria S, Gibson T, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 216(3):380-9, 2013.
  35. Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. Cancer. 125 (6), 854-862, 2019.
  36. Shah C, Zambelli-Weiner A, Delgado N, Sier A, Bauserman R, Nelms J. The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements. Breast Cancer Res Treat. 185(3):709-740, 2021.
  37. Whitworth P, Vicini F, Valente SA, et al. Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data. J Cancer Surviv. 18(2):344-351, 2024.
  38. Shah C, Boyages J, Koelmeyer L, Chen SL, Vicini F. Timing of breast cancer related lymphedema development over 3 years: observations from a large, prospective randomized screening trial comparing bioimpedance spectroscopy (BIS) versus tape measure. Ann Surg Oncol. 31(11):7487-7495, 2024.
  39. Gratzon A, Schultz J, Secrest K, Lee K, Feiner J, Klein RD. Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy. Ann Surg Oncol. 24(6):1475-1481, 2017.
  40. Paramanandam VS, Dylke E, Clark GM, et al. Prophylactic use of compression sleeves reduces the incidence of arm swelling in women at high risk of breast cancer-related lymphedema: a randomized controlled trial. J Clin Oncol. 40(18):2004-2012, 2022.
  41. Gratzon A, Schultz J, Secrest K, Lee K, Feiner J, Klein RD. Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy. Ann Surg Oncol. 24(6):1475-1481, 2017.
  42. Silva AK, Chang DW. Vascularized lymph node transfer and lymphovenous bypass: Novel treatment strategies for symptomatic lymphedema. J Surg Oncol. 113(8):932-9, 2016.
  43. Siotos C, Hassanein AH, Bello RJ, et al. Delayed breast reconstruction on patients with upper extremity lymphedema: a systematic review of the literature and pooled analysis. Ann Plast Surg. 81(6):730-735, 2018.
  44. Ammitzbøll G, Johansen C, Lanng C, et al. Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial. Cancer. 125(10):1683-1692, 2019.
  45. Hasenoehrl T, Palma S, Ramazanova D, et al. Resistance exercise and breast cancer-related lymphedema-a systematic review update and meta-analysis. Support Care Cancer. 28(8):3593-3603, 2020.
  46. Paskett ED, Le-Rademacher J, Oliveri JM, et al. A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 127(2):291-299, 2021.
  47. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 361(7):664-73, 2009.
  48. Speck RM, Gross CR, Hormes JM, et al. Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema. Breast Cancer Res Treat. 121(2):421-30, 2010.
  49. Baumann FT, Reike A, Reimer V, et al. Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat. 170(1):1-13, 2018.
  50. Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 51 (11): 2375-2390, 2019.
  51. National Cancer Institute. Lymphedema – patient version. https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema, 2024.
  52. Guzzo HM, Valente SA, Schwarz GS, et al. Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction. Breast Cancer Res Treat. 196(3):657-664, 2022.
  53. Copeland-Halperin LR, Hyland CJ, Gadiraju GK, et al. Preoperative risk factors for lymphedema in inflammatory breast cancer. J Reconstr Microsurg. 40(4):311-317, 2024.
  54. Holmberg L, Iverson OE, Rudenstam CM, et al., for the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 100(7):475-82, 2008.
  55. Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 49(1):52-9, 2013.
  56. Mudhune GH, Armour M, McBride KA. Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: a systematic review and meta-analysis. Breast. 47:43-55, 2019.
  57. Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 191(2):269-275, 2022.
  58. Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat.135:603–9, 2012.
  59. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. Committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 127(3):e93-6, 2016.
  60. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 25(1):11-20, 2018.
  61. Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 26(6):603-610, 2018.
  62. Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 114(10):1347-1354, 2022.
  63. Kastora SL, Pantiora E, Hong YH, et al. Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: a meta-analysis based expert panel discussion. Cancer Treat Rev. 133:102880, 2025.
  64. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 29(7):767-794, 2022.
  65. Mazzarello S, Hutton B, Ibrahim MF, et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat. 152(1):1-8, 2015.
  66. Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 3(3):313-319, 2017.
  67. Barbieri RL. Patient education: Menopausal hormone therapy (Beyond the Basics). In: UpToDate (Snyder PJ, Martin KA, eds.). https://www.uptodate.com/contents/menopausal-hormone-therapy-beyond-the-basics. Waltham, MA: UpToDate, 2025.
  68. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 33(30):3394-400, 2015.
  69. The Menopause Society. Menopause topics: hot flashes. https://menopause.org/patient-education/menopause-topics/hot-flashes, 2025.
  70. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 27(17):2831-7, 2009.
  71. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 28(20):3278-83, 2010.
  72. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 305(3):267-74, 2011.
  73. Pinkerton JV, Constantine G, Hwang E, et al. for the Study 3353 Investigators. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 20(1):28-37, 2013.
  74. Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M for the Breeze 3 Investigators. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause. 21(6):567-73, 2014.
  75. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 29(1):204-13, 2014.
  76. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 174(7):1058-66, 2014.
  77. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 340:c693, 2010.
  78. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 401(10382):1091-1102, 2023.
  79. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: A Phase 3 RCT. J Clin Endocrinol Metab. 108(8):1981-1997, 2023.
  80. Cardoso F, Parke S, Brennan DJ, et al. Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N Engl J Med. 393(8):753-763, 2025.
  81. Yoon SH, Lee JY, Lee C, Lee H, Kim SN. Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. Menopause. 27(4):485-493, 2020.
  82. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 366(9488):818-24, 2005.
  83. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 28(35):5147-52, 2010.
  84. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 28(4):641-7, 2010.
  85. Boekhout AH, Vincentb AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 29(29):3862-8, 2011.
  86. North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 22(11):1155-72, 2015.
  87. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 25(6):596-608, 2018.
  88. Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr. 4(1):pkz088, 2019.
  89. U.S. Food and Drug Administration. Lynkuet (elinzanetant) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf, 2025.
  90. Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev. 7:CD007410, 2013.
  91. Chiu HY, Pan CH, Shyu YK, Han BC, Tsai PS. Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials. Menopause. 22(2):234-44, 2015.
  92. Garcia MK, Graham-Getty L, Haddad R, et al. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer. 121(22):3948-58, 2015.
  93. Ee C, Xue C, Chondros P, et al. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med. 164(3):146-54, 2016.
  94. Lu W, Giobbie-Hurder A, Tanasijevic A, et al. Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials. Cancer. 130(18):3219-3228, 2024.
  95. Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 30(33):4124-33, 2012.
  96. Zachariae R, Amidi A, Damholdt MF, et al. Internet-delivered cognitive-behavioral therapy for insomnia in breast cancer survivors: a randomized controlled trial. J Natl Cancer Inst. 110(8):880-887, 2018.
  97. Atema V, van Leeuwen M, Kieffer JM, et al. Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Clin Oncol. 37(10):809-822, 2019.
  98. Hummel SB, van Lankveld JJDM, Oldenburg HSA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol. 35(12):1328-1340, 2017.
  99. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. (4):CD001395, 2007.
  100. Bolaños R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause. 17(3):660-6, 2010.
  101. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med. 171(15):1363-9, 2011.
  102. Amato P, Young RL, Steinberg FM, et al. Effect of soy isoflavone supplementation on menopausal quality of life. Menopause. 20(4):443-7, 2013.
  103. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 9:CD007244, 2012.
  104. Pruthi S, Qin R, Terstreip SA, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 19(1):48-53, 2012.
  105. Reed SD, Guthrie KA, Newton KM, et al. Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol. 210(3):244, 2014.
  106. Zhu X, Liew Y, Liu ZL. Chinese herbal medicine for menopausal symptoms. Cochrane Database Syst Rev. 3:CD009023, 2016.
  107. U.S. Food and Drug Administration (FDA). Menopause & hormones. https://www.fda.gov/media/130242/download, 2019.
  108. Stuenkel CA. Compounded bioidentical hormone therapy: new recommendations from the 2020 National Academies of Sciences, Engineering, and Medicine. Menopause. 28(5):576-578, 2021.
  109. Partridge AH, Niman SM, Ruggeri M, et al. for the International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 388(18):1645-1656, 2023.
  110. Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 31(1):73-9, 2013.
  111. Iqbal J, Amir E, Rochon PA, Giannakeas V, Sun P, Narod SA. Association of the timing of pregnancy with survival in women with breast cancer. JAMA Oncol. 2017 May 1;3(5):659-665, 2017.
  112. Lambertini M, Kroman N, Ameye L, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 110(4):426-429, 2018.
  113. Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 39(29):3293-3305, 2021.
  114. Rauh-Hain JA, Zubizarreta J, Nitecki R, et al. Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study. Cancer. 128(17):3243-3253, 2022.
  115. Arecco L, Blondeaux E, Bruzzone M, et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis. ESMO Open. 8(6):102031, 2023.
  116. Johnson HM, Mitchell KB. Breastfeeding and breast cancer: managing lactation in survivors and women with a new diagnosis. Ann Surg Oncol. 26(10):3032-3039, 2019.
  117. Blasingame M, Kuller JA, Dotters-Katz SK, Trotter K, Kerner N. Contraceptive use in breast cancer patients and survivors. Obstet Gynecol Surv. 80(11):711-716, 2025.
  118. Lengacher CA, Reich RR, Paterson CL, et al. Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 34(24):2827-34, 2016.
  119. Sharpe L, Turner J, Fardell JE, et al. for the ConquerFear Authorship group. Psychological intervention (ConquerFear) for treating fear of cancer recurrence: mediators and moderators of treatment efficacy. J Cancer Surviv. 13(5):695-702, 2019.
  120. Park SY, Lim JW. Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature. BMC Cancer. 22(1):217, 2022.
  121. Nguyen P, Heisey R, Quenneville C, et al. An examination of depression, anxiety, and fear of recurrence among cancer survivors who participated in a virtual cognitive behavioral therapy (CBT)-based telephone coaching program. Support Care Cancer. 30(9):7323-7332, 2022.
  122. Carlson RW. Chapter 67: Surveillance of patients following primary therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  123. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 34(9):927-35, 2016.
  124. Lee JM, Buist DS, Houssami N, et al. Five-year risk of interval-invasive second breast cancer. J Natl Cancer Inst. 107(7), 2015.
  125. Ricceri F, Fasanelli F, Giraudo MT, et al. Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 137(4):940-8, 2015.
  126. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment—breast, ovarian and pancreatic cancer. Version 3.2026. http://www.nccn.org, 2026.
  127. Giannakeas V, Lim DW, Narod SA. Bilateral mastectomy and breast cancer mortality. JAMA Oncol. 10(9):1228-1236, 2024.
  128. Davies C, Godwin J, Gray R, et al. for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378(9793):771-84, 2011.
  129. Dowsett M, Forbes JF, Bradley R, et al. for the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 386(10001):1341-52, 2015.
  130. Kramer I, Schaapveld M, Oldenburg HSA, et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J Natl Cancer Inst. 111(7):djz010, 2019.
  131. Björneklett HG, Lindemalm C, Rosenblad A, et al. A randomised controlled trial of support group intervention after breast cancer treatment: results on anxiety and depression. Acta Oncol. 51(2):198-207, 2012.
  132. Kroenke CH, Kwan ML, Neugut AI, et al. Social networks, social support mechanisms, and quality of life after breast cancer diagnosis. Breast Cancer Res Treat. 139(2):515-27, 2013.
  133. Leung J, Pachana NA, McLaughlin D. Social support and health-related quality of life in women with breast cancer: a longitudinal study. Psychooncology. 23(9):1014-20, 2014.
  134. Durá-Ferrandis E, Mandelblatt JS, Clapp J, et al. Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance). Psychooncology. 26(11):1914-1921, 2017.
  135. Brandão T, Schulz MS, Matos PM. Psychological adjustment after breast cancer: a systematic review of longitudinal studies. Psychooncology. 26(7):917-926, 2017.
  136. Krasne M, Ruddy KJ, Poorvu PD, et al. Coping strategies and anxiety in young breast cancer survivors. Support Care Cancer. 30(11):9109-9116, 2022.
  137. Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in Adult Survivors of Cancer: ASCO Guideline Update. J Clin Oncol. 41(18):3426-3453, 2023.
  138. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Distress management. V.2.2025. http://www.nccn.org, 2025.
  139. Huang HP, He M, Wang HY, Zhou M. A meta-analysis of the benefits of mindfulness-based stress reduction (MBSR) on psychological function among breast cancer (BC) survivors. Breast Cancer. 23(4):568-76, 2016.
  140. Lyman GH, Greenlee H, Bohlke K, e al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol. 1;36(25):2647-2655, 2018.
  141. Schell LK, Monsef I, Wöckel A, Skoetz N. Mindfulness-based stress reduction for women diagnosed with breast cancer. Cochrane Database Syst Rev. 3(3):CD011518, 2019.
  142. Bower JE, Partridge AH, Wolff AC, et al. Targeting depressive symptoms in younger breast cancer survivors: The Pathways to Wellness randomized controlled trial of mindfulness meditation and survivorship education. J Clin Oncol. 39(31):3473-3484, 2021.
  143. Escalante CP. Cancer-related fatigue: treatment. In: UpToDate (Hesketh PJ, Ganz PA, Vora SR, eds.). Waltham, MA: UpToDate, 2025.
  144. van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: the SWORD study, a randomized controlled trial. J Clin Oncol. 35(19):2173-2183, 2017.
  145. Abrahams HJG, Gielissen MFM, Donders RRT, et al. The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial. Cancer. 123(19):3825-3834, 2017.
  146. Compen F, Bisseling E, Schellekens M, et al. Face-to-face and internet-based mindfulness-based cognitive therapy compared with treatment as usual in reducing psychological distress in patients with cancer: a multicenter randomized controlled trial. J Clin Oncol. 36(23):2413-2421, 2018.
  147. Rosendahl J, Gawlytta R, Ressel E, et al. Efficacy of group therapy to reduce mental distress in women with non-metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Psychooncology. 32(3):331-341, 2023.
  148. Montgomery GH, David D, Kangas M, et al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. J Clin Oncol. 32(6):557-63, 2014.
  149. Garland SN, Carlson LE, Stephens AJ, Antle MC, Samuels C, Campbell TS. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 32(5):449-57, 2014.
  150. Roscoe JA, Garland SN, Heckler CE, et al. Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. J Clin Oncol. 33(2):165-71, 2015.
  151. Irwin MR, Olmstead R, Carrillo C, et al. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 35(23):2656-2665, 2017.
  152. Garland SN, Xie SX, DuHamel K, et al. Acupuncture versus cognitive behavioral therapy for insomnia in cancer survivors: a randomized clinical trial. J Natl Cancer Inst. 111(12):1323-1331, 2019.
  153. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 11:CD006145, 2012.
  154. Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 15:77, 2015.
  155. Rogers LQ, Courneya KS, Anton PM, et al. Effects of a multicomponent physical activity behavior change intervention on fatigue, anxiety, and depressive symptomatology in breast cancer survivors: randomized trial. Psychooncology. 26(11):1901-1906, 2017.
  156. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 3(7):961-968, 2017.
  157. Falcetta FS, de Araújo Vianna Träsel H, de Almeida FK, Rangel Ribeiro Falcetta M, Falavigna M, Dornelles Rosa D. Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 170(3):455-476, 2018.
  158. Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY. The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer. Cancer. 124(4):797-806, 2018.
  159. Baglia ML, Lin IH, Cartmel B, et al. Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. Cancer. 125(13):2262-2271, 2019.
  160. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 40(22):2491-2507, 2022.
  161. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Cancer-related fatigue. V.1.2026. http://www.nccn.org/, 2026.
  162. Lu Q, Gallagher MW, Loh A, Young L. Expressive writing intervention improves quality of life among Chinese-American breast cancer survivors: a randomized controlled trial. Ann Behav Med. 52(11):952-962, 2018.
  163. Oberguggenberger A, Martini C, Huber N, et al. Self-reported sexual health: Breast cancer survivors compared to women from the general population – an observational study. BMC Cancer. 17(1):599, 2017.
  164. Bober SL, Krapf J. Overview of sexual dysfunction in female cancer survivors, in Up-to-Date (Ganz PA, Yushak M, eds.). Up-to-Date, 2025.
  165. Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 8:CD007566, 2012.
  166. von Hippel C, Rosenberg SM, Austin SB, et al. Identifying distinct trajectories of change in young breast cancer survivors’ sexual functioning. Psychooncology. 28(5):1033-1040, 2019.
  167. Rosenberg SM, Dominici LS, Gelber S, et al. Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors.JAMA Surg. 155(11):1035-1042, 2020.
  168. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 358: 1389-99, 2001.
  169. Shiyanbola OO, Arao RF, Miglioretti DL, et al. Emerging trends in family history of breast cancer and associated risk. Cancer Epidemiol Biomarkers Prev. 26(12):1753-1760, 2017.
  170. Mukama T, Kharazmi E, Sundquist K, Sundquist J, Brenner H, Fallah M. Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history. Cancer. 126(12):2837-2848, 2020.
  171. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast Cancer Res Treat. 144(1):185-92, 2014.
  172. U.S. Department of Health and Human Services. The Health Consequences of Smoking — 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
  173. Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 70(4):245-271, 2020.
  174. Reese JB, Lepore SJ, Sorice KA, et al. Efficacy of a couple-based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial. Cancer. 131(1):e35685, 2025.
  175. Villa P, Cassani C, Nappi RE, et al. Quality of life and satisfaction with ospemifene for treating vulvovaginal atrophy in breast cancer survivors: six-month results from the PatiEnt SatisfactiON StudY (PEONY). Clin Breast Cancer. 25(8):782-791, 2025.
  176. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 111(2):329-42, 2008.
  177. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 123(3):627-35, 2010.
  178. Ewertz M, Jensen MB, Gunnarsdóttir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 29(1):25-31, 2011.
  179. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer. 15:865, 2015.
  180. Cecchini R, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev. 25(1):51-9, 2016.
  181. Nichols HB, Trentham-Dietz A, Egan KM, et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 18(5):1403-9, 2009.
  182. Bradshaw PT, Ibrahim JG, Stevens J, et al. Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology. 23(2):320-327, 2012.
  183. Jung AY, Hüsing A, Behrens S, et al. Postdiagnosis weight change is associated with poorer survival in breast cancer survivors: A prospective population-based patient cohort study. Int J Cancer. 148(1):18-27, 2021.
  184. Centers for Disease Control and Prevention. How overweight and obesity impacts your health. https://www.cdc.gov/healthy-weight-growth/food-activity/overweight-obesity-impacts-health.html, 2025.
  185. American Cancer Society. Excess body weight and cancer risk. https://www.cancer.org/cancer/risk-prevention/diet-physical-activity/body-weight-and-cancer-risk.html, 2025.
  186. Rock CL, Natarajan L, Pu M, et al. for the Women’s Healthy Eating and Living Study Group. Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women’s Healthy Eating and Living Study. Cancer Epidemiol Biomarkers Prev. 18(2):486-94, 2009.
  187. Beasley JM, Newcomb PA, Trentham-Dietz A, et al. Post-diagnosis dietary factors and survival after invasive breast cancer. Breast Cancer Res Treat. 128(1):229-36, 2011.
  188. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer. 127(1):172-84, 2010.
  189. O’Connor EA, Evans CV, Ivlev I, et al. Vitamin and mineral supplements for the primary prevention of cardiovascular disease and cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 327(23):2334-2347, 2022.
  190. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 98(24):1767-76, 2006.
  191. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA. 298(3):289-98, 2007.
  192. Holmes MD, Chen WY, Hankinson SE, Willett WC. Physical activity’s impact on the association of fat and fiber intake with survival after breast cancer. Am J Epidemiol. 170(10):1250-56, 2009.
  193. Chlebowski RT, Aragaki AK, Anderson GL, et al. for the Women’s Health Initiative. Dietary modification and breast cancer mortality: long-term follow-up of the Women’s Health Initiative randomized trial. J Clin Oncol. 38(13):1419-1428, 2020.
  194. Cannioto RA, Attwood KM, Davis EW, et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 6(5):e2311673, 2023.
  195. Tang L, Wang Z, Hsiao HH, et al. Associations of cruciferous vegetable intake with breast cancer survival in a diverse population in the Pathways Study. Cancer Epidemiol Biomarkers Prev. 34(7):1177-1187, 2025.
  196. Farvid MS, Holmes MD, Chen WY, et al. Postdiagnostic fruit and vegetable consumption and breast cancer survival: prospective analyses in the Nurses’ Health Studies. Cancer Res. 80(22):5134-5143, 2020.
  197. Shu XO, Zheng Y, Cai H, et al. Soy food intake and breast cancer survival. JAMA. 302(22):2437-43, 2009.
  198. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 96(1):123-32, 2012.
  199. Chi F, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 14(4):2407-12, 2013.
  200. Zhang FF, Haslam DE, Terry MB, et al. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer. 123(11):2070-2079, 2017.
  201. van Die MD, Bone KM, Visvanathan K, et al. Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies. JNCI Cancer Spectr. 8(1):pkad104, 2024.
  202. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 98(1):9-14, 2008.
  203. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 125(2): p. 315-23, 2011.
  204. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 57(5):260-77, 2007.
  205. Touillaud M, Gelot A, Mesrine S, et al. Use of dietary supplements containing soy isoflavones and breast cancer risk among women aged >50 y: a prospective study. Am J Clin Nutr. 109(3):597-605, 2019.
  206. Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol. 28(29):4410-6, 2010.
  207. Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 19(3):681-8, 2010.
  208. Kwan ML, Chen WY, Flatt SW, et al. Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 22(1):32-41, 2013.
  209. Newcomb PA, Kampman E, Trentham-Dietz A, et al. Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol. 31(16):1939-46, 2013.
  210. Ali AM, Schmidt MK, Bolla M, et al. Alcohol consumption and survival after a breast cancer diagnosis: A literature-based meta-analysis and collaborative analysis of data for 29,239 cases. Cancer Epidemiol Biomarkers Prev. 23(6):934-45, 2014.
  211. Lowry SJ, Kapphahn K, Chlebowski R, Li CI. Alcohol use and breast cancer survival among participants in the Women’s Health Initiative. Cancer Epidemiol Biomarkers Prev. 25(8):1268-73, 2016.
  212. Nomura T, Kawai M, Fukuma Y, et al. Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition. Breast Cancer. 30(4):519-530, 2023.
  213. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med. 332(19):1245-50, 1995.
  214. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 302(4):401-11, 2009.
  215. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 17(2):379-86, 2008.
  216. Chen X, Lu W, Zheng W, et al. Exercise after diagnosis of breast cancer in association with survival. Cancer Prev Res (Phila). 4(9):1409-18, 2011.
  217. Nechuta S, Chen WY, Cai H, et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer. 138(9):2088-97, 2016.
  218. Maliniak ML, Patel AV, McCullough ML, et al. Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res Treat. 167(1):133-145, 2018.
  219. Friedenreich CM, Stone CR, Cheung WY, Hayes SC. Physical activity and mortality in cancer survivors: a systematic review and meta-analysis. JNCI Cancer Spectr. 4(1):pkz080, 2019.
  220. Salam A, Woodman A, Chu A, et al. Effect of post-diagnosis exercise on depression symptoms, physical functioning and mortality in breast cancer survivors: A systematic review and meta-analysis of randomized control trials. Cancer Epidemiol. 77:102111, 2022.
  221. Fortner RT, Brantley KD, Tworoger SS, et al. Physical activity and breast cancer survival: results from the Nurses’ Health Studies. JNCI Cancer Spectr. 7(1):pkac085, 2023.
  222. Rees-Punia E, Teras LR, Newton CC, et al. Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysis. J Natl Cancer Inst. 117(8):1689-1698, 2025.
  223. Wilson OW, Matthews CE, Wojcik KM, et al. The effects of post-diagnosis recreational aerobic exercise among breast cancer survivors: a systematic review/meta-analyses. Cancer Epidemiol Biomarkers Prev. 34(8):1252-1263, 2025.
  224. Jones LW, Habel LA, Weltzien E, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol. 34(23):2743-9, 2016.
  225. Wu AH, Gomez SL, Vigen C, et al. The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. Cancer Causes Control. 24(10):1821-36, 2013.
  226. Pierce JP, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the after breast cancer pooling project. J Natl Cancer Inst. 106(1):djt359, 2014.
  227. Passarelli MN, Newcomb PA, Hampton JM, et al. Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer and smoking-related diseases. J Clin Oncol. 34(12):1315-22, 2016.
  228. U.S. Department of Health and Human Services. The Health Consequences of Smoking — 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
  229. Wang L, Hong BY, Kennedy SA, et al. Predictors of unemployment after breast cancer surgery: a systematic review and meta-analysis of observational studies. J Clin Oncol. 36(18):1868-1879, 2018.
  230. Ekenga CC, Pérez M 2, Margenthaler JA, Jeffe DB. Early-stage breast cancer and employment participation after 2 years of follow-up: A comparison with age-matched controls. Cancer. 124(9):2026-2035,2018.
  231. Rosenberg SM, Vaz-Luis I, Gong J, et al. Employment trends in young women following a breast cancer diagnosis. Breast Cancer Res Treat. 177(1):207-214, 2019.
  232. Dumas A, Vaz Luis I, Bovagnet T, et al. Impact of breast cancer treatment on employment: results of a multicenter prospective cohort study (CANTO). J Clin Oncol. 38(7):734-743, 2020.
  233. Emerson MA, Reeve BB, Gilkey MB, Elmore SNC, et al. Job loss, return to work, and multidimensional well-being after breast cancer treatment in working-age Black and White women. J Cancer Surviv. 17(3):805-814, 2023.
  234. Blinder VS, Patil S, Thind A, et al. Return to work in low-income Latina and non-Latina white breast cancer survivors: A 3-year longitudinal study. Cancer. 118(6):1664-74, 2012.
  235. Lundh MH, Lampic C, Nordin K, et al. Changes in health-related quality of life by occupational status among women diagnosed with breast cancer-a population-based cohort study. Psychooncology. 22(10):2321-31, 2013.
  236. Liou KT, Bradt J, Currier MB, et al. Music therapy versus cognitive behavioral therapy via telehealth for anxiety in cancer survivors: a randomized clinical trial. J Clin Oncol. 2026 Jan 6 [Online ahead of print].
  237. U.S. Food and Drug Administration. Veozah (fezolinetant) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf, 2024.
  238. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 347:1713-27, 1996.
  239. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control. 8:65-72, 1997.
  240. Ruddy KJ and Ginsburg ES. Chapter 90: Reproductive issues in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  241. Azim Jr HA, Niman SM, Partridge AH, et al. Fertility preservation and assisted reproduction in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy. J Clin Oncol. 42(23):2822-2832, 2024.
  242. Marklund A, Lundberg FE, Eloranta S, et al. Reproductive outcomes after breast cancer in women with vs without fertility preservation. JAMA Oncol. 7(1):86-91, 2021.
  243. Greer AC, Lanes A, Poorvu PD, et al. The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. Cancer. 127(20):3872-3880, 2021.
  244. Marklund A, Lekberg T, Hedayati E, et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 8(10):1438-1446, 2022.
  245. Wang Y, Tesch ME, Lim C, et al. Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation. Breast Cancer Res Treat. 195(2):201-208, 2022.
  246. Moore HC, Unger JM, Phillips KA, et al. for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 372(10):923-32, 2015.
  247. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2(1):65-73, 2016.
  248. Lambertini M, Boni L, Michelotti A, et al. For the GIM study group. Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients. J Natl Cancer Inst. 114(3):400-408, 2022.
  249. American Cancer Society. American Cancer Society Guideline for Diet and Physical Activity. https://www.cancer.org/cancer/risk-prevention/diet-physical-activity/acs-guidelines-nutrition-physical-activity-cancer-prevention/guidelines.html, 2025.

Updated 03/26/26

 

TOOLS & RESOURCES

PDF

Fact Sheet

Support After a Breast Cancer Diagnosis

PDF

Fact Sheet

What is Breast Cancer?